期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 192, 期 6, 页码 1026-1030出版社
WILEY
DOI: 10.1111/bjh.16722
关键词
AML; MRD; NPM1; venetoclax
类别
资金
- Leukemia & Lymphoma Society (LLS) Specialized Center of Research (SCOR)
- Medical Research Future Fund (MRFF)
- NIHR RM/ICR Biomedical Research Centre
This study demonstrates the significant efficacy of venetoclax-based therapy in reducing the risk of relapse in patients with persistent or rising NPM1(mut) MRD.
Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1(mut) measurable residual disease (MRD) using off-label venetoclax in combination with low-dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, including five with molecular persistence and seven with molecular relapse/progression. All patients with molecular persistence achieved durable molecular complete remission (CRMRD-) without transplantation. Six of seven patients with molecular relapse/progression achieved CRMRD- after 1-2 cycles of venetoclax. This paper highlights the promising efficacy of venetoclax-based therapy to reduce the relapse risk in patients with persistent or rising NPM1(mut) MRD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据